{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/regeneron-regn/",
 "dataUrl": "https://clearank.com/stock/regeneron-regn/data.json",
 "title": "Regeneron (REGN) Stock Forecast & Price Target (2026)",
 "description": "Regeneron Pharmaceuticals, Inc. (REGN) stock: Healthcare, Biotechnology. $81.1B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Regeneron Pharmaceuticals, Inc. (REGN)",
 "published": "2026-06-23T09:09:57+00:00",
 "modified": "2026-09-26T15:56:36.337+00:00",
 "generated": "2026-09-27T14:26:11.612Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "REGN",
  "name": "Regeneron Pharmaceuticals, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.regeneron.com"
 },
 "quote": {
  "price": 788.04,
  "previousClose": 796.02,
  "change": -7.98,
  "changePercent": -1,
  "open": 803.87,
  "high": 803.87,
  "low": 784.13,
  "volume": 592100,
  "averageVolume": 791040,
  "marketCap": 81132646478,
  "fiftyTwoWeekHigh": 859.34003,
  "fiftyTwoWeekLow": 541,
  "marketOpen": false,
  "asOf": "2026-09-26T15:56:36.000Z"
 },
 "statistics": {
  "pe": 19.69859,
  "eps": 40.41,
  "dividendYield": 0.004775634001479889,
  "beta": 0.193,
  "priceToSales": 5.27556,
  "priceToBook": 2.5181663,
  "revenueTtm": 15534699520,
  "grossMargin": 0.8656396392197078,
  "returnOnEquity": 0.14043
 },
 "technicals": {
  "rsi": 35.08,
  "macd": 1.88,
  "sma50": 776.79,
  "sma200": 735.69,
  "rsiSignal": "Bearish",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 68,
  "consensus": "Buy",
  "fairValue": 854,
  "analystTarget": 854,
  "analystCount": 28,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-26T15:56:36.000Z",
  "priceAtAnalysis": 788.039978,
  "volatility": {
   "daily": 1.67,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 772.28,
  "aggressiveEntry": 788.04,
  "stopLoss": 743.09,
  "stopLossPercent": 3.78,
  "targets": [
   810.89,
   849.51,
   888.12
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 558.86,
    "base": 843.51,
    "upside90th": 1273.16
   },
   {
    "year": 2028,
    "downside10th": 504.42,
    "base": 902.9,
    "upside90th": 1616.16
   },
   {
    "year": 2029,
    "downside10th": 473.71,
    "base": 966.46,
    "upside90th": 1971.76
   },
   {
    "year": 2030,
    "downside10th": 454.1,
    "base": 1034.49,
    "upside90th": 2356.7
   },
   {
    "year": 2031,
    "downside10th": 441.05,
    "base": 1107.32,
    "upside90th": 2780.07
   },
   {
    "year": 2032,
    "downside10th": 432.39,
    "base": 1185.27,
    "upside90th": 3249.06
   },
   {
    "year": 2033,
    "downside10th": 426.9,
    "base": 1268.7,
    "upside90th": 3770.44
   },
   {
    "year": 2034,
    "downside10th": 423.85,
    "base": 1358.02,
    "upside90th": 4351.08
   },
   {
    "year": 2035,
    "downside10th": 422.75,
    "base": 1453.62,
    "upside90th": 4998.24
   },
   {
    "year": 2036,
    "downside10th": 423.27,
    "base": 1555.95,
    "upside90th": 5719.73
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "REGN Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$803.87",
    "Day Range": "$784.13 to $803.87",
    "Prev Close": "$796.02",
    "Volume": "592.1K",
    "52-Week Range": "$541.00 to $859.34",
    "Market Cap": "$81.13B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-38%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "REGN Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, REGN beat estimates 3 times. The stock rose 2 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "REGN Analysis",
   "text": [
    "Regeneron Pharmaceuticals, Inc. (REGN) is showing bearish momentum according to its RSI of 35.08, suggesting a potential pullback. The stock is trading below its 20-day EMA of $796.38 but remains above its 50-day SMA of $776.79 and its 200-day SMA of $735.69, indicating that the longer-term trend is still positive. Volume has been below average recently, with a 25.1% decrease compared to the average daily volume. The current price action suggests that the 50-day SMA is acting as support, while the 20-day EMA presents near-term resistance. Investors should monitor the RSI for signs of reversal from its oversold territory.",
    "Regeneron Pharmaceuticals (REGN) reported an EPS surprise of 39.96% for the quarter ending June 2026, significantly exceeding analyst expectations and driving positive stock movement.",
    "Analysts forecast substantial revenue growth for REGN in the current year, indicating strong market demand for its products and services.",
    "Insiders have sold approximately $12.9 million worth of REGN stock with no reported purchases, indicating a moderate sell signal from management.",
    "Regeneron Pharmaceuticals (REGN) is trading above its 50-day and 200-day moving averages ($776.79 and $735.69), suggesting underlying support despite short-term bearish momentum.",
    "The base case for Regeneron Pharmaceuticals, Inc. (REGN) anticipates continued growth driven by strong product demand and pipeline advancements, supporting a potential move towards its median analyst target price of $854.00 within the next 6-12 months. The company's projected revenue growth of 18.00% for the current year and an average of 10.5% over the next five years indicate sustained expansion. Upside catalysts could include successful clinical trial results for new therapies or stronger-than-expected earnings reports, potentially pushing the stock towards its higher price targets. Conversely, increased competition, regulatory hurdles, or a broader market downturn could pressure the stock, with downside risks potentially leading it towards the lower end of analyst targets or even its long-range projection downside of $454.10."
   ],
   "lists": {
    "ProTips": [
     "Monitor the RSI for a potential reversal from its current bearish reading as the stock approaches its 50-day SMA support level.",
     "Given the moderate insider selling, pay close attention to any future insider transactions for further clues on management's confidence.",
     "Consider the premium price-to-sales ratio relative to sector peers as a potential valuation risk, even with strong growth prospects."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Earnings Beat in June 2026 Quarter",
     "text": "Regeneron Pharmaceuticals (REGN) reported an EPS surprise of 39.96% for the quarter ending June 2026, significantly exceeding analyst expectations and driving positive stock movement.",
     "source": "Company Earnings Report"
    },
    {
     "type": "Bullish",
     "title": "Projected Revenue Growth of 18.00% for Current Year",
     "text": "Analysts forecast substantial revenue growth for REGN in the current year, indicating strong market demand for its products and services.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Signal",
     "text": "Insiders have sold approximately $12.9 million worth of REGN stock with no reported purchases, indicating a moderate sell signal from management.",
     "source": "Insider Transactions"
    },
    {
     "type": "Neutral",
     "title": "Trading Above Key Moving Averages",
     "text": "Regeneron Pharmaceuticals (REGN) is trading above its 50-day and 200-day moving averages ($776.79 and $735.69), suggesting underlying support despite short-term bearish momentum.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Regeneron Pharmaceuticals, Inc. (REGN) trades at a P/E ratio of 19.70, which is below the healthcare sector median of 31.90, suggesting a potential valuation discount relative to peers. The company's price-to-sales ratio stands at 5.28, also below the sector median of 3.70, indicating it trades at a premium on a sales basis. However, its return on equity is a strong 14.04%, significantly higher than the sector average of 6.9%. With a profit margin of 27.87% and an operating margin of 33.11%, Regeneron demonstrates superior profitability compared to the sector. The company's debt-to-equity ratio is a healthy 0.09, indicating a strong balance sheet. These fundamentals, combined with strong revenue growth, support the current valuation despite the premium on a price-to-sales basis.",
    "Regeneron Pharmaceuticals, Inc. (REGN) delivered a strong earnings surprise of 39.96% in the quarter ending June 2026, with actual EPS of $14.29 significantly beating the estimate of $10.21, leading to a 3.29% price increase. This follows a pattern of positive earnings surprises in recent quarters, with the exception of the March 2026 quarter which missed estimates. The company is projected to achieve revenue growth of 21.00% year-over-year for the current quarter, indicating continued top-line expansion.",
    "Regeneron Pharmaceuticals, Inc. (REGN) faces risks related to insider selling, with $12.9 million in sales recorded against no purchases, signaling a moderate sell signal from management. The stock's current valuation, particularly its price-to-sales ratio of 5.28, is at a premium compared to the sector average of 3.70. Additionally, while the RSI is currently bearish at 35.08, a sustained move below the 50-day SMA could indicate further downside pressure."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "81.13B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "19.70"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "40.41"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.47%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "859.34"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "541.00"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Bearish SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($776.79) above the 200-day SMA ($735.69), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Bearish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "35.08"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "1.88"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "776.79"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "735.69"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.28",
    "Correlation with Nasdaq 100 (QQQ)": "+0.20",
    "Correlation with Bitcoin (BTC)": "-0.09",
    "Correlation with Gold (XAU)": "+0.06"
   }
  },
  {
   "id": "trade-plans",
   "title": "REGN Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (35.1) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$810.89",
    "TARGET 2": "$849.51",
    "TARGET 3": "$888.12",
    "STOP LOSS": "$743.09"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-0.33%",
    "Average Feb return": "+2.47%",
    "Average Mar return": "+1.99%",
    "Average Apr return": "-4.40%",
    "Average May return": "-0.41%",
    "Average Jun return": "+4.08%",
    "Average Jul return": "+3.28%",
    "Average Aug return": "+4.62%",
    "Average Sep return": "-2.76%",
    "Average Oct return": "-3.67%",
    "Average Nov return": "+2.95%",
    "Average Dec return": "-0.84%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.67%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in REGN in September 2016 would be worth about $19,500 today, compared with about $36,004 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in REGN today could grow to about $19,745 by 2036 in the base case, with a bull case near $72,582 and a bear case around $5,371. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "REGN Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $1,034 for REGN by 2030 in the base case, from $788 today (1.3x over 4 years). The downside path ends near $454. These are outcomes of a Monte Carlo simulation run on REGN's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using REGN's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "REGN simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$559",
        "$844",
        "$1,273"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$504",
        "$903",
        "$1,616"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$474",
        "$966",
        "$1,972"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$454",
        "$1,034",
        "$2,357"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$441",
        "$1,107",
        "$2,780"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$432",
        "$1,185",
        "$3,249"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$427",
        "$1,269",
        "$3,770"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$424",
        "$1,358",
        "$4,351"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$423",
        "$1,454",
        "$4,998"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$423",
        "$1,556",
        "$5,720"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "UNH UnitedHealth Group Inc. NYSE $376.59 +0.42%",
     "url": "https://clearank.com/stock/unitedhealth-group-unh/"
    },
    {
     "text": "REPL Replimune Group, Inc. NASDAQ $12.36 -1.90%",
     "url": "https://clearank.com/stock/repl-stock-analysis/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $190.86 -1.27%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "NTRA Natera, Inc. NASDAQ $412.56 +0.92%",
     "url": "https://clearank.com/stock/natera-ntra/"
    },
    {
     "text": "GEHC GE HealthCare Technologies Inc. NASDAQ $66.63 +0.38%",
     "url": "https://clearank.com/stock/ge-healthcare-gehc/"
    },
    {
     "text": "NEOG Neogen Corp. NASDAQ $13.76 +0.73%",
     "url": "https://clearank.com/stock/neogen-neog/"
    },
    {
     "text": "BMY Bristol-Myers Squibb Company NYSE $62.86 +2.21%",
     "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
    },
    {
     "text": "CRNX Crinetics Pharmaceuticals, Inc. NASDAQ $84.95 +0.00%",
     "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare REGN",
   "links": [
    {
     "text": "VRTX vs REGN Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vrtx-vs-regn/"
    },
    {
     "text": "XRP/USD vs HBAR/USD Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/xrp-vs-hbar/"
    },
    {
     "text": "VOO vs VOOG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/voo-vs-voog/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "REGN Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$12.9M",
    "Insiders": "19",
    "Avg Transaction": "$860.4K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in REGN",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "May 29, 2020",
       "cells": [
        "SANOFI SA Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "22.8M",
        "$11.6B"
       ]
      },
      {
       "label": "Aug 19, 2021",
       "cells": [
        "SCHLEIFER LEONARD S Chief Executive Officer",
        "Sell",
        "210.0K",
        "$136.6M"
       ]
      },
      {
       "label": "May 12, 2020",
       "cells": [
        "SCHLEIFER LEONARD S Chief Executive Officer",
        "Sell",
        "150.9K",
        "$85.9M"
       ]
      },
      {
       "label": "May 21, 2020",
       "cells": [
        "VAGELOS P ROY Chairman of the Board",
        "Sell",
        "148.8K",
        "$84.0M"
       ]
      },
      {
       "label": "Jun 9, 2020",
       "cells": [
        "SANOFI SA Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "120.2K",
        "$71.8M"
       ]
      },
      {
       "label": "May 15, 2024",
       "cells": [
        "YANCOPOULOS GEORGE D President",
        "Sell",
        "50.0K",
        "$48.8M"
       ]
      },
      {
       "label": "May 16, 2024",
       "cells": [
        "YANCOPOULOS GEORGE D President",
        "Sell",
        "50.0K",
        "$48.6M"
       ]
      },
      {
       "label": "Jun 21, 2021",
       "cells": [
        "YANCOPOULOS GEORGE D President",
        "Sell",
        "80.0K",
        "$43.1M"
       ]
      },
      {
       "label": "Aug 24, 2020",
       "cells": [
        "SING GEORGE LOUIS Director",
        "Sell",
        "61.0K",
        "$36.9M"
       ]
      },
      {
       "label": "May 15, 2024",
       "cells": [
        "SCHLEIFER LEONARD S Chief Executive Officer",
        "Sell",
        "35.9K",
        "$35.2M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Regeneron+Pharmaceuticals%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Regeneron Pharmaceuticals' stock price forecast for 2030?",
   "answer": "Regeneron Pharmaceuticals' (REGN) stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $1034.49, with a downside scenario of $454.10 and an upside scenario of $2356.70. These figures represent statistical outcomes, not guaranteed price targets."
  },
  {
   "question": "Is Regeneron Pharmaceuticals stock a buy right now?",
   "answer": "Regeneron Pharmaceuticals (REGN) currently holds a 'Buy' consensus rating from Wall Street analysts, supported by strong revenue growth and consistent earnings beats. The median analyst price target of $854.00 suggests an 8.4% upside from the current price of $788.04."
  },
  {
   "question": "What are the key risks for Regeneron Pharmaceuticals?",
   "answer": "Key risks for Regeneron Pharmaceuticals (REGN) include moderate insider selling totaling $12.9 million, a premium valuation on a price-to-sales basis compared to sector peers, and a bearish RSI indicating potential short-term weakness."
  },
  {
   "question": "How does Regeneron Pharmaceuticals compare to its sector averages?",
   "answer": "Regeneron Pharmaceuticals (REGN) demonstrates superior revenue growth (16.7% vs. 8.1% sector median) and profitability (ROE 14.04% vs. 6.9% sector median). While its P/E is lower than the sector median, its price-to-sales ratio is higher."
  },
  {
   "question": "What was Regeneron Pharmaceuticals' most recent earnings performance?",
   "answer": "In the quarter ending June 2026, Regeneron Pharmaceuticals (REGN) reported an EPS surprise of 39.96%, with actual EPS of $14.29 exceeding estimates of $10.21, leading to a 3.29% stock price increase."
  },
  {
   "question": "What is Regeneron Pharmaceuticals' dividend yield?",
   "answer": "Regeneron Pharmaceuticals (REGN) offers a dividend yield of approximately 0.47%, with a dividend rate of $3.70."
  },
  {
   "question": "What is the overall sentiment from Wall Street analysts on REGN stock?",
   "answer": "Wall Street sentiment for Regeneron Pharmaceuticals (REGN) is predominantly positive, with 28 analysts covering the stock. The consensus is 'Buy', comprising 4 'Strong Buy' ratings, 14 'Buy' ratings, and 9 'Hold' ratings, resulting in a Wall Street score of 68 out of 100."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "UNH",
    "name": "UnitedHealth Group Inc. NYSE",
    "price": "$376.59",
    "change": "+0.42%",
    "url": "https://clearank.com/stock/unitedhealth-group-unh/"
   },
   {
    "ticker": "REPL",
    "name": "Replimune Group, Inc. NASDAQ",
    "price": "$12.36",
    "change": "-1.90%",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$190.86",
    "change": "-1.27%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "NTRA",
    "name": "Natera, Inc. NASDAQ",
    "price": "$412.56",
    "change": "+0.92%",
    "url": "https://clearank.com/stock/natera-ntra/"
   },
   {
    "ticker": "GEHC",
    "name": "GE HealthCare Technologies Inc. NASDAQ",
    "price": "$66.63",
    "change": "+0.38%",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "NEOG",
    "name": "Neogen Corp. NASDAQ",
    "price": "$13.76",
    "change": "+0.73%",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "BMY",
    "name": "Bristol-Myers Squibb Company NYSE",
    "price": "$62.86",
    "change": "+2.21%",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
   },
   {
    "ticker": "CRNX",
    "name": "Crinetics Pharmaceuticals, Inc. NASDAQ",
    "price": "$84.95",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   }
  ],
  "comparisons": [
   {
    "ticker": "VRTX vs REGN Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vrtx-vs-regn/"
   },
   {
    "ticker": "XRP/USD vs HBAR/USD Comparison",
    "name": "",
    "url": "https://clearank.com/compare/xrp-vs-hbar/"
   },
   {
    "ticker": "VOO vs VOOG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/voo-vs-voog/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "SYY",
    "text": "Sysco Corp.",
    "url": "https://clearank.com/stock/syy-stock-analysis/"
   },
   {
    "ticker": "FIS",
    "text": "Fidelity National Information Services, Inc.",
    "url": "https://clearank.com/stock/fis-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "CRDO",
    "text": "↑ 7.65%",
    "url": "https://clearank.com/stock/credo-crdo/"
   },
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   },
   {
    "ticker": "GRT/USD",
    "text": "↑ 20.82%",
    "url": "https://clearank.com/crypto/the-graph-grt/"
   },
   {
    "ticker": "SEI/USD",
    "text": "↑ 19.29%",
    "url": "https://clearank.com/crypto/sei-sei/"
   },
   {
    "ticker": "WLD/USD",
    "text": "↑ 17.41%",
    "url": "https://clearank.com/crypto/worldcoin-wld/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "MRNA",
    "text": "Moderna, Inc.",
    "url": "https://clearank.com/stock/moderna-mrna/"
   },
   {
    "ticker": "REPL",
    "text": "Replimune",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "RGNX",
    "text": "REGENXBIO",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/"
   },
   {
    "ticker": "RXRX",
    "text": "Recursion",
    "url": "https://clearank.com/stock/rxrx-stock-analysis/"
   },
   {
    "ticker": "VKTX",
    "text": "Viking Therapeutics Inc",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/regn-analysis-2026-06.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/regn-analysis-2026-06.png",
     "width": "1280",
     "height": "720",
     "caption": "Regeneron Pharmaceuticals (REGN) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/regeneron-regn/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/regeneron-regn/",
        "name": "Regeneron Pharmaceuticals (REGN) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/regeneron-regn/#webpage",
     "url": "https://clearank.com/stock/regeneron-regn/",
     "name": "Regeneron (REGN) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-23T09:09:57+00:00",
     "dateModified": "2026-09-26T15:56:36+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/regn-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/regeneron-regn/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/regeneron-regn/#richSnippet",
     "headline": "Regeneron (REGN) Stock Forecast & Price Target (2026)",
     "name": "Regeneron (REGN) Stock Forecast & Price Target (2026)",
     "description": "Regeneron Pharmaceuticals, Inc. (REGN) stock: Healthcare, Biotechnology. $81.1B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-06-23T09:09:57+00:00",
     "dateModified": "2026-09-26T15:56:36+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Regeneron Pharmaceuticals, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "REGN"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, an",
      "tickerSymbol": "REGN",
      "sameAs": "https://www.regeneron.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/regeneron-regn/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/regn-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/regeneron-regn/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Regeneron Pharmaceuticals' stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Regeneron Pharmaceuticals' (REGN) stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $1034.49, with a downside scenario of $454.10 and an upside scenario of $2356.70. These figures represent statistical outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is Regeneron Pharmaceuticals stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Regeneron Pharmaceuticals (REGN) currently holds a 'Buy' consensus rating from Wall Street analysts, supported by strong revenue growth and consistent earnings beats. The median analyst price target of $854.00 suggests an 8.4% upside from the current price of $788.04."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks for Regeneron Pharmaceuticals?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks for Regeneron Pharmaceuticals (REGN) include moderate insider selling totaling $12.9 million, a premium valuation on a price-to-sales basis compared to sector peers, and a bearish RSI indicating potential short-term weakness."
     }
    },
    {
     "@type": "Question",
     "name": "How does Regeneron Pharmaceuticals compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Regeneron Pharmaceuticals (REGN) demonstrates superior revenue growth (16.7% vs. 8.1% sector median) and profitability (ROE 14.04% vs. 6.9% sector median). While its P/E is lower than the sector median, its price-to-sales ratio is higher."
     }
    },
    {
     "@type": "Question",
     "name": "What was Regeneron Pharmaceuticals' most recent earnings performance?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "In the quarter ending June 2026, Regeneron Pharmaceuticals (REGN) reported an EPS surprise of 39.96%, with actual EPS of $14.29 exceeding estimates of $10.21, leading to a 3.29% stock price increase."
     }
    },
    {
     "@type": "Question",
     "name": "What is Regeneron Pharmaceuticals' dividend yield?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Regeneron Pharmaceuticals (REGN) offers a dividend yield of approximately 0.47%, with a dividend rate of $3.70."
     }
    },
    {
     "@type": "Question",
     "name": "What is the overall sentiment from Wall Street analysts on REGN stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Wall Street sentiment for Regeneron Pharmaceuticals (REGN) is predominantly positive, with 28 analysts covering the stock. The consensus is 'Buy', comprising 4 'Strong Buy' ratings, 14 'Buy' ratings, and 9 'Hold' ratings, resulting in a Wall Street score of 68 out of 100."
     }
    }
   ]
  }
 ]
}